Flosin B

Flosin B: A Comprehensive Reference Article

1. Identity: Botanical Source, Chemical Name, and Natural Occurrence

Flosin B is a naturally occurring polyphenolic compound belonging to the chemical class of ellagitannins — specifically a subgroup of hydrolysable tannins built on a hexahydroxydiphenic acid (HHDP) core esterified to a glucose backbone. It is a type of ellagitannin classified as a hexahydroxydiphenic acid derivative contained in the water-soluble fraction of banaba leaf extract. Flosin B is chemically considered an epimer of lagerstroemin, the principal ellagitannin of its plant source, and the two compounds share close structural relationship; the total amount of lagerstroemin and its epimer, Flosin B, and Reginin A, contained in banaba extract can be obtained as lactonized valoneic acid.

Seven ellagitannins, lagerstroemin (1), flosin B (2), stachyurin (3), casuarinin (4), casuariin (5), epipunicacortein A (6), and 2,3-(S)-hexahydroxydiphenoyl-alpha/beta-D-glucose (7) have been identified by bioassay-directed isolation from the leaves of Lagerstroemia speciosa (L.) Pers. The chemical structures of these compounds are established by one- and two-dimensional NMR spectroscopy and high-resolution mass spectrometric analysis.

The primary botanical source of Flosin B is Lagerstroemia speciosa (L.) Pers., a member of the family Lythraceae, commonly known as banaba, crepe myrtle, pride of India, queen's crepe myrtle, or queen's flower. Banaba is a semideciduous, tropical, flowering tree that grows in India, Southeast Asia, and the Philippines. L. speciosa, commonly planted as an ornamental along roadsides and in gardens and parks, can grow up to 20 m in height. The leaves are obovate, simple, and opposite. The flowers are pink to purple when in bloom and give way to oval, nut-like fruits. The bark of the tree peels off in flakes.

Flosin B is not considered the primary or most abundant active ingredient of banaba leaf. The primary active chemical ingredient of banaba extract is corosolic acid, and there are also numerous possible synergists including lager-stroemin, Flosin B and reginin A. Flosin B is found together with these other ellagitannins in the water-soluble fraction of the leaf extract, as distinguished from corosolic acid, which partitions into the less water-soluble fraction. Other known compounds, including corosolic acid, gallic acid, 4-hydroxybenzoic acid, 3-O-methylprotocatechuic acid, caffeic acid, p-coumaric acid, kaempferol, quercetin, and isoquercitrin, have also been isolated from the same plant.

Flosin B has also been reported in other members of the genus Lagerstroemia. Structure elucidation of three new monomeric and dimeric ellagitannins, flosin B and reginins C and D, isolated from Lagerstroemia species has been described in the phytochemical literature. Additionally, flosin B has been identified among C-glycosidic ellagitannins, together with pedunculagin, lythracin D, and lagerstroemin, in isolation studies on the genus.

Common Forms and Preparations

In commerce and research, Flosin B is not typically sold as an isolated ingredient. Instead, it is encountered as a constituent of banaba leaf extract, which is available in several formulations:

• Standardized dry-powder extracts, most commonly standardized to a defined percentage of corosolic acid (commonly 1%, 2%, up to 20%, or higher) by HPLC, with ellagitannins including Flosin B present as a complementary fraction.
• Soft-gel capsules using a lipid vehicle to enhance bioavailability of the corosolic acid fraction; Glucosol in a soft gel capsule formulation showed a 30% decrease in blood glucose levels compared to a 20% drop seen with dry-powder filled hard gelatin capsule formulation, suggesting that the soft gel formulation has better bioavailability.
• Hard gelatin or vegetarian capsules filled with dry powder.
• Leaf tea/decoction, which is the traditional preparation and results in a water-soluble extract that is particularly rich in ellagitannins such as Flosin B, lagerstroemin, and reginin A.
• Tablets, including products such as "Banabamin," a tablet form containing aqueous banaba extract that has been marketed as a health food in Japan. Banabamin, which is a tablet containing extract from banaba tea, has been already marketed in Japan as a food to promote health.

2. Traditional and Historical Use

Banaba (Lagerstroemia speciosa L.) extracts have been used for many years in folk medicine to treat diabetes, with the first published research study being reported in 1940. The plant's medicinal history is particularly deep in the Philippines, India, and the broader Southeast Asian region.

The Philippines

Filipinos consume the leaves of Lagerstroemia speciosa as herbal tea for lowering blood sugar level and reducing body weight. Lagerstroemia speciosa, commonly known as "Pride of India," belongs to the Lythraceae family. Lagerstroemia speciosa or Banaba is a medicinal tree traditionally used to lower blood sugar in the body. It is known in Tagalog as "banaba," and the plant is one of the most recognized traditional medicinal plants of the Philippine pharmacopeia. Folkloric use of banaba leaf decoctions for diuretic and purgative purposes, and of the bark and root parts for stomach ailments, has also been recorded. The traditional preparation of the leaf as a tea or decoction — producing a water-soluble extract — would logically concentrate the water-soluble ellagitannin fraction, which includes Flosin B, alongside other constituents.

Leaves of the species have been traditionally used over thousands of years as folkloric treatment by native populations for illness and ailments, particularly for lowering blood sugar levels and weight loss. Traditionally, leaves, bark and roots of Lagerstroemia speciosa have been used in folk medicines and are remedies for various illnesses and ailments. Leaves have been used to treat diabetes mellitus and serve as diuretic and decongestant. Roots are used for treating mouth ulcers and bark is used as stimulant, for relief of abdominal pains and as febrifuge.

India and the Broader Region

Lagerstroemia speciosa L. (Family Lythraceae), commonly known as banaba or crepe myrtle, has a hot water extract from its leaves that is used to treat diabetes as a folk medicine in Asia. In India, the plant is also known as "Pride of India," and its traditional uses encompass blood sugar management, kidney and bladder support, and treatment of hypertension. Banaba is also recommended in traditional medicine for kidney and bladder problems and hypertension.

Japan and Taiwan

The leaves of the banaba and other parts are used widely by the Philippines, Taiwan, and Japan as a tea preparation. In Japan, banaba has been incorporated into the commercial food supplement market in the form of standardized tablets and tea products. The first research study evaluating the insulin-like activity of an aqueous extract of dried leaves was conducted in rabbits and published in 1940. This early research, performed in the Philippines, established the scientific foundation for the centuries-old folk usage and initiated a line of inquiry into which specific phytochemicals — eventually including Flosin B — were responsible for the observed effects.

Traditional Preparations

Across all traditional cultures in which banaba leaf was used, the predominant preparation was an aqueous decoction or tea — the dried or fresh leaves were boiled in water and the liquid was consumed. This preparation method selectively extracts the water-soluble fraction of the leaf, which modern phytochemical analysis has shown to be rich in ellagitannins including Flosin B, lagerstroemin, and reginin A. The bark and root were more commonly used as tonics, stimulants, or for gastrointestinal complaints, while the leaf was the primary source for antidiabetic use.

3. Key Constituents and Active Compounds in Context

To understand Flosin B's pharmacological significance, it is necessary to situate it within the broader phytochemical composition of the banaba leaf. More than 40 compounds are identified and documented from plant leaves. The major bioactive categories are:

• Triterpenoids: Principally corosolic acid (2α-hydroxyursolic acid), the most studied compound from banaba and the standard marker compound for commercial extracts.
• Ellagitannins: A group of water-soluble polyphenols including lagerstroemin, Flosin B, reginin A, stachyurin, casuarinin, casuariin, and epipunicacortein A.
• Ellagic acid and its derivatives: Including 3-O-methylellagic acid, 3,3'-di-O-methylellagic acid, 3,4,3'-tri-O-methylellagic acid, and 3-O-methyl-ellagic acid 4'-sulfate.
• Flavonoids: Including kaempferol, quercetin, and isoquercitrin.
• Gallic acid and phenolic acids: Including 4-hydroxybenzoic acid, caffeic acid, and p-coumaric acid.
• Gallotannins: Including penta-O-galloyl-glucopyranose (PGG), hypothesized to have glucose transport-stimulating activity.

The obtained ellagitannins exhibited strong activities in both stimulating insulin-like glucose uptake and modulating adipocyte differentiation in cell-based assays. Flosin B is isolated as compound number 2 (or sometimes compound 42, depending on the numbering system of the relevant study) in comprehensive isolation studies of the leaf.

4. Mechanisms of Action

The established and hypothesized mechanisms of Flosin B and the closely related ellagitannins of banaba are primarily centered on glucose metabolism and insulin signaling. These have been elucidated through in vitro and animal model studies; direct mechanistic data for isolated Flosin B in humans is not established in the available literature.

4.1 GLUT4 Activation and Glucose Uptake

Glucose transport enhancers were searched for in Lagerstroemia speciosa, a Philippine local herbal medicine used for diabetes mellitus. Bioassay-guided fractionation of the aqueous acetone extract of the leaves afforded three active ellagitannins, lagerstroemin, flosin B and reginin A, identified by NMR and optical rotation. These compounds increased glucose uptake of rat adipocytes, and could be responsible for lowering the blood glucose level. This pivotal finding, published in the journal Planta Medica (Hayashi et al., 2002) and indexed on PubMed (PMID 11859474), is the foundational scientific evidence for Flosin B's biological activity.

Lagerstroemin, flosin B, and reginin A have been shown to regulate blood glucose levels. These compounds promote glucose uptake by activating glucose transporter type 4 (GLUT4), a protein responsible for transporting glucose from the blood into muscle cells and adipocytes. GLUT4 is the principal insulin-regulated glucose transporter in peripheral tissues; its activation without requiring insulin itself is a mechanism sometimes described as "insulin-like."

4.2 Phosphatidylinositol 3-Kinase (PI3K) Signaling

Flosin B is found to have an effect via phosphatidylinositol 3-kinase (PI3K). Specifically, a hexahydroxydiphenic acid derivative has an insulin-like action via a glucose uptake promoting activity in peripheral tissues and a sugar transporter type 4 (GLUT4) present in cells. It was elucidated that the epimers flosin B and reginin A also have the above-mentioned insulin-like action. PI3K is a central node in the canonical insulin signaling cascade; its activation by insulin normally leads to downstream activation of Akt (protein kinase B), which in turn triggers GLUT4 translocation to the plasma membrane. The ellagitannins including Flosin B appear to stimulate or converge on this pathway.

4.3 Insulin Receptor Activation and MAPK Signaling

A possible mechanism of antidiabetic effect by tannins such as lagerstroemin through activation of insulin receptors was suggested from studies on Chinese hamster ovary cells expressing human insulin receptors where an increased in mitogen-activated protein kinases (MAPK) activity coupled with increased tyrosine-phosphorylation of the β-subunit of the insulin receptors was induced by the compound (Hattori et al., 2003). This mechanism — involving direct interaction with or modulation of the insulin receptor — parallels that described for flosin B and reginin A, given their close structural relationship to lagerstroemin.

4.4 PPAR Modulation

At the level of the whole-plant extract, banaba and its constituents have been linked to peroxisome proliferator-activated receptor (PPAR) modulation. Enhanced expression of peroxisome proliferator-activated receptor (PPAR-α) in the liver and PPAR-γ in white adipose tissue (WAT) were observed. The increased expression of liver PPAR-α mRNA and adipose tissue PPAR-γ mRNA in animals as a mechanism of action for banaba in db/db mice were also reported along with improvement in insulin sensitivity and hyperglycaemia. Whether these effects are attributable specifically to Flosin B or primarily to corosolic acid cannot be definitively separated in the available literature.

4.5 Alpha-Glucosidase and Alpha-Amylase Inhibition

Another report noted inhibitory effects of banaba on postprandial hyperglycemia via inhibition of alpha-amylase and alpha-glucosidases. Alpha-glucosidase inhibition slows the digestion and absorption of carbohydrates from the small intestine, thereby attenuating the postprandial rise in blood glucose. This mechanism complements the direct glucose transport-enhancing effects of ellagitannins such as Flosin B.

4.6 Effects on GLUT4 Versus Ellagic Acid Derivatives

An important nuance in the mechanistic picture is that not all phytochemicals from banaba activate GLUT4. Ellagitannins from L. speciosa activated GLUT4, while ellagic acid derivatives showed an inhibitory effect. Research has compared the anti-diabetic effects of several extracts from leaves of L. speciosa using different manufacturing processes based on the contents of ellagitannins and ellagic acid derivatives. This finding has direct practical implications for the manufacture of banaba extracts: processing methods that convert ellagitannins (such as Flosin B) to ellagic acid derivatives may actually reduce or antagonize the glucose transport-stimulating activity of the extract.

5. Scientific Evidence by Area of Use

5.1 Blood Glucose Regulation and Antidiabetic Activity

In Vitro Evidence

The foundational in vitro study is the Hayashi et al. (2002) paper (PubMed PMID: 11859474), which used bioassay-guided fractionation of aqueous acetone leaf extracts to identify Flosin B, lagerstroemin, and reginin A as the active ellagitannins promoting glucose uptake in rat adipocytes. Glucose transport enhancers were searched for in Lagerstroemia speciosa, a Philippine local herbal medicine used for diabetes mellitus. Bioassay-guided fractionation of the aqueous acetone extract of the leaves afforded three active ellagitannins, lagerstroemin, flosin B and reginin A, identified by NMR and optical rotation. These compounds increased glucose uptake of rat adipocytes, and could be responsible for lowering the blood glucose level.

A subsequent study by Bai et al. (2008), published in the Journal of Agricultural and Food Chemistry, extended this work: Seven ellagitannins — lagerstroemin (1), flosin B (2), stachyurin (3), casuarinin (4), casuariin (5), epipunicacortein A (6), and 2,3-(S)-hexahydroxydiphenoyl-α/β-d-glucose (7), together with one ellagic acid sulfate, ellagic acid, and four methyl ellagic acid derivatives — were identified by the bioassay-directed isolation from the leaves of Lagerstroemia speciosa (L.) Pers. This study confirmed the GLUT4-activating activity of the ellagitannin fraction including Flosin B, and also identified opposing inhibitory effects from ellagic acid derivatives.

Evidence strength (in vitro): Consistent. Multiple independent studies have replicated the glucose uptake-enhancing activity of the ellagitannin fraction in cell-based systems.

Animal Model Evidence

The hypoglycemic effects of banaba have been attributed to both corosolic acid as well as ellagitannins. Studies have been conducted in various animal models, human subjects, and in vitro systems using water-soluble banaba leaf extracts, corosolic acid, and ellagitannins. Animal studies have demonstrated blood glucose lowering and antiobesity effects of banaba extracts in rodent models, including genetically diabetic KK-Ay mice. However, since these studies typically used whole leaf extracts rather than isolated Flosin B, the specific contribution of Flosin B to the observed in vivo effects cannot be separated from those of corosolic acid, lagerstroemin, and other constituents.

Evidence strength (animal): Moderate, for the extract as a whole. Specific in vivo data for isolated Flosin B is not available in the indexed literature.

Human Clinical Evidence

Clinical trials have been conducted on banaba leaf extracts as a whole, not on isolated Flosin B. The antidiabetic activity of an extract from the leaves of Lagerstroemia speciosa standardized to 1% corosolic acid (Glucosol) has been demonstrated in a randomized clinical trial involving type II diabetics (NIDDM). Subjects received a daily oral dose of Glucosol and blood glucose levels were measured. Glucosol at daily dosages of 32 and 48 mg for 2 weeks showed a significant reduction in blood glucose levels.

Twenty-four human subjects with mild type 2 diabetes were given three tablets three times daily. A 13.5% average decrease in blood glucose levels was reported, and no adverse effects were observed. The constituents in the product responsible for the antidiabetic effect were not determined. This is a notable limitation: in studies using multi-constituent products (including green tea, green coffee, and Garcinia), the specific contribution of the banaba ellagitannins including Flosin B cannot be isolated.

In a study published by Tsuchibe et al., 12 non-diabetic subjects with a baseline blood glucose level of 104 mg/dL were given a soft gel capsule daily for 2 weeks containing 10 mg corosolic acid as a banaba extract standardized to 18% corosolic acid. A 12% decrease in fasting as well as 60-minute postprandial blood glucose levels was observed after 2 weeks. The authors also reported an average three-pound weight loss after the 2 weeks. No adverse effects were observed during or after the trial. Although this product contained a high level of corosolic acid, it is not clear if the effect was entirely due to the corosolic acid or a combination of the corosolic acid with tannin components.

Regarding the mechanisms of action involved in the beneficial effects of banaba, most studies have focused on corosolic acid, which is isolated with an organic solvent from banaba leaves, and include the regulation of different carbohydrate metabolic pathways, enhancement of cellular glucose uptake, inhibition of the hydrolysis of different disaccharides, and the regulation of PPAR-α and γ.

A 2022 randomized, double-blind, placebo-controlled clinical trial by López-Murillo et al. (published in the Journal of Medicinal Food) evaluated banaba in metabolic syndrome: this study was a single-center, randomized, double-blind, parallel, placebo-controlled clinical trial with a 12-week treatment period in 24 patients with metabolic syndrome. This study investigated effects on insulin sensitivity and insulin secretion, representing one of the more rigorously designed trials to date, though the small sample size (N=24) limits the generalizability of its findings.

Evidence strength (human): Preliminary to weak for isolated or well-characterized ellagitannin effects, including Flosin B specifically. Reviews of medical literature on the effects of banaba in diabetes have identified few quality clinical trials and some open-label or small studies. Clinical trial data are lacking to recommend banaba for any indication. The evidence base for banaba extract as a whole on blood glucose is promising but limited by small study sizes, heterogeneous product formulations, short durations (often two weeks), and an inability to attribute effects specifically to ellagitannins versus corosolic acid.

5.2 Lipid Metabolism and Antiobesity Activity

Animal studies have suggested that banaba extracts may reduce body fat and hepatic lipid accumulation. In an animal study conducted by Suzuki et al. (1999), it was shown that banaba extracts induced weight loss and reduced adipose tissue weight. Additionally, a significant drop of up to 65% in hepatic lipids was observed. The beneficial effects of banaba and corosolic acid with respect to various aspects of glucose and lipid metabolism appear to involve multiple mechanisms, including enhanced cellular uptake of glucose, impaired hydrolysis of sucrose and starches, decreased gluconeogenesis, and the regulation of lipid metabolism.

Studies have also shown improvement in insulin sensitivity, increased plasma adiponectin, and white adipose tissue (WAT) AdipoR1 levels after corosolic acid administration. The adiponectin-raising effect is of interest because adiponectin is an insulin-sensitizing adipokine whose levels are typically reduced in obesity and type 2 diabetes.

Evidence strength (antiobesity): Preclinical (animal). There is insufficient human clinical evidence specifically for Flosin B or the ellagitannin fraction on body weight or fat mass.

5.3 Antioxidant Activity

Corosolic acid also exhibits antihyperlipidemic, antioxidant, anti-inflammatory, antifungal, antiviral, antineoplastic and osteoblastic activities. These activities have been described primarily for corosolic acid but are reported in the context of banaba extracts that necessarily contain ellagitannins including Flosin B. One 15-day study in rats found that 68 mg per pound (150 mg per kg) of body weight of banaba leaf extract neutralized free radicals and other reactive species while regulating levels of antioxidant enzymes. Still, human studies on the antioxidant effects of banaba leaves are lacking.

In vitro, various in vitro studies involving cell-free systems and cell cultures have demonstrated antioxidant and osteoblastic activities of banaba extracts and corosolic acid. Ellagitannins as a class are known to be potent antioxidants; Flosin B, as a member of this class, shares structural features associated with free-radical scavenging capacity, though its specific antioxidant potency relative to other banaba ellagitannins has not been separately reported in indexed literature.

Evidence strength (antioxidant): In vitro and animal data exist for banaba extracts. No human clinical evidence specifically for Flosin B's antioxidant effects.

5.4 Anti-inflammatory Activity

Lagerstroemia speciosa extract has been reported to inhibit TNF-induced activation of nuclear factor-kappaB (NF-κB) in rat cardiomyocyte H9c2 cells, pointing to potential anti-inflammatory mechanisms. NF-κB is a key transcription factor in inflammation, and its inhibition is a mechanism shared by several polyphenolic compounds. The relevance of Flosin B specifically to this mechanism is not established separately from the broader extract.

The beneficial effects of banaba and corosolic acid with respect to various aspects of glucose and lipid metabolism appear to involve multiple mechanisms, including enhanced cellular uptake of glucose, impaired hydrolysis of sucrose and starches, decreased gluconeogenesis and the regulation of lipid metabolism. These effects may be mediated by PPAR, MAPK, NF-κB and other signal transduction factors.

Evidence strength (anti-inflammatory): Preclinical only. No controlled human trials specifically examining anti-inflammatory effects of Flosin B or the banaba ellagitannin fraction.

5.5 Xanthine Oxidase Inhibition

Research has also examined inhibitory effects of banaba leaf extracts on xanthine oxidase, an enzyme involved in uric acid production and a target relevant to gout management. Xanthine oxidase inhibitors from the leaves of Lagerstroemia speciosa (L.) Pers. have been investigated in ethnopharmacological research (Unno et al., 2004). This line of research is preliminary and has not been extended to clinical trials specifically for Flosin B.

6. Body Systems and Health Areas of Association

Based on the available preclinical and clinical literature on banaba extracts and the role of ellagitannins including Flosin B, the following body systems and health areas are associated with this compound:

• Endocrine / Metabolic system: Primary area of study. Insulin-like glucose uptake promotion, GLUT4 activation, improved insulin sensitivity, and effects on metabolic syndrome components.
• Cardiovascular system: Corosolic acid-mediated antihyperlipidemic effects and PPAR-α-related regulation of lipid metabolism; NF-κB-mediated cardioprotective potential at the extract level.
• Adipose tissue / Body weight regulation: Preclinical evidence of reduced fat accumulation and hepatic lipid content.
• Renal / Urinary system: Traditional use as a diuretic; some research into kidney-protective effects. Antioxidants in banaba extract may protect the kidneys from damage caused by chemotherapy drugs.
• Digestive system: Alpha-glucosidase and alpha-amylase inhibition, which affects carbohydrate digestion and postprandial blood glucose.
• Oxidative stress / Antioxidant defense: Free-radical scavenging and regulation of antioxidant enzymes in animal studies.

7. Dosage Forms and Dosages Reported in Studies

Flosin B is not available or studied in isolation as a standalone supplement ingredient at defined dosages in the indexed clinical literature. All dosage information pertains to banaba leaf extracts in which Flosin B is a constituent of the ellagitannin fraction. The following dosages have been reported in the cited scientific literature:

• 32 mg/day and 48 mg/day of Glucosol (banaba leaf extract standardized to 1% corosolic acid) for 2 weeks, administered to type 2 diabetic subjects: Glucosol at daily dosages of 32 and 48 mg for 2 weeks showed a significant reduction in blood glucose levels.
• 10 mg corosolic acid daily (delivered as banaba extract standardized to 18% corosolic acid) for 2 weeks in 12 non-diabetic subjects: 12 non-diabetic subjects were given a soft gel capsule daily for 2 weeks containing 10 mg corosolic acid as a banaba extract standardized to 18% corosolic acid. A 12% decrease in fasting as well as 60-minute postprandial blood glucose levels was observed.
• 100 mg/day of water-soluble banaba extract for 1 year in an open-label study: Ikeda et al. conducted a 1-year open label safety and efficacy study on 15 subjects, administering 100 mg tablets daily of a water-soluble banaba extract. The extract was not standardized, and the constituent(s) responsible for the antidiabetic effects was not determined.
• Three tablets three times daily of Banabamin (aqueous banaba extract combined with other herbal ingredients) in 24 subjects with mild type 2 diabetes: twenty-four human subjects with mild type 2 diabetes were given three tablets three times daily, and a 13.5% average decrease in blood glucose levels was reported.

Clinical trial data are lacking to recommend banaba for any indication. Limited clinical trial data exist to provide dosing recommendations. No dosage specifically for isolated Flosin B has been established in clinical research.

8. Safety Considerations and Interactions

Safety

No adverse effects have been observed or reported in animal studies or controlled human clinical trials of banaba extract. This applies to the extract as a whole, which necessarily includes the ellagitannin fraction of which Flosin B is a part. Both animal and human studies agree that the use of banaba leaves and their extracts as herbal remedies appears to be safe. Contraindications have not been identified in the reviewed literature, and no toxicity has been reported.

Information regarding safety and efficacy in pregnancy and lactation is lacking. This absence of safety data in special populations should be noted; the conventional precaution in the absence of evidence is to avoid use in these populations.

Drug Interactions

No drug interactions with banaba are well documented. However, theoretical interactions are relevant given the mechanism of action of Flosin B and the banaba ellagitannin fraction:

• Antidiabetic medications (insulin, sulfonylureas, metformin, GLP-1 agonists): Because Flosin B and the banaba ellagitannin fraction promote glucose uptake via a GLUT4/insulin-like mechanism, additive blood glucose-lowering effects with antidiabetic drugs are biologically plausible. This would represent a theoretical risk of hypoglycemia, although this has not been documented in clinical trials reviewed in the available literature.
• Antihypertensive agents: Traditional use of banaba for blood pressure management raises the theoretical possibility of additive effects with antihypertensive drugs, though no clinical interaction data are available.

Quality and Extract Composition Variability

A practical safety-adjacent concern is the significant variability in the composition of banaba leaf extracts on the market. Ellagitannins from L. speciosa activated GLUT4, while ellagic acid derivatives showed an inhibitory effect. Since manufacturing processes (particularly those involving heat, acid hydrolysis, or prolonged extraction) can convert ellagitannins to ellagic acid and its methyl derivatives — compounds that have the opposite effect on GLUT4 — the ratio of active ellagitannins (including Flosin B) to ellagic acid derivatives in a commercial product may vary substantially. This means that extracts standardized only to corosolic acid content may not reflect or ensure any particular level of Flosin B or the broader ellagitannin fraction.

9. Summary of Evidence Strength

A growing body of evidence involving animal and human studies as well as in vitro systems indicates that banaba leaf extracts exert antidiabetic and antiobesity effects. There is strong evidence to indicate that corosolic acid as well as ellagitannins is responsible for these effects. Flosin B's role within this picture is as one of three identified active ellagitannins (alongside lagerstroemin and reginin A) with demonstrated glucose transport-stimulating activity in cell-based assays. Its individual contribution to clinical outcomes in humans has not been established, as no clinical trial has used isolated Flosin B as the test substance. The scientific investigation of Flosin B remains at the in vitro and preclinical stage for its independent effects, while evidence for the extract mixture (which includes Flosin B as a constituent) is limited by the quality and scale of available clinical trials.

It is thought that the active constituents of the banaba leaf are corosolic acid and ellagitannins (lagerstroemin, flosin B, and reginin A). This characterization, from an NCBI Bookshelf chapter on complementary and integrative approaches to type 2 diabetes management, reflects the current scientific consensus: Flosin B is accepted as one of the likely active constituents of banaba leaf, but the evidence base for its effects in isolation or in specific dosage in humans remains to be established through well-designed, adequately powered clinical trials.

References

• Hayashi T, et al. Ellagitannins from Lagerstroemia speciosa as activators of glucose transport in fat cells. Planta Medica. 2002. PubMed PMID: 11859474
• Stohs SJ, et al. Management of Diabetes and Its Complications with Banaba (Lagerstroemia speciosa L.) and Corosolic Acid. Journal of Evidence-Based Complementary & Alternative Medicine. 2012. PMC3468018
• Stohs SJ, Miller H, Kaats GR. A Review of the Efficacy and Safety of Banaba (Lagerstroemia speciosa L.) and Corosolic Acid. Phytotherapy Research. 2012;26:317–324.
• Bai N, et al. Active Compounds from Lagerstroemia speciosa, Insulin-like Glucose Uptake-Stimulatory/Inhibitory and Adipocyte Differentiation-Inhibitory Activities in 3T3-L1 Cells. Journal of Agricultural and Food Chemistry. 2008.
• McKennon SA. Non-Pharmaceutical Intervention Options For Type 2 Diabetes: Complementary & Integrative Health Approaches. In: Endotext [Internet]. NCBI Bookshelf, NIH.
• Lagerstroemia – ScienceDirect Topics (Pharmacology, Toxicology and Pharmaceutical Science overview)
• López-Murillo LD, et al. Effect of Banaba (Lagerstroemia speciosa) on Metabolic Syndrome, Insulin Sensitivity, and Insulin Secretion. Journal of Medicinal Food. 2022.
• Bai N, et al. Chemical constituents from leaves of Lagerstroemia speciosa L. ResearchGate / Journal of Agricultural and Food Chemistry. 2008.
• Kakuda T, et al. Antidiabetes and Anti-Obesity Activity of Lagerstroemia speciosa. ResearchGate.
• Ulbricht C, et al. Banaba (Lagerstroemia speciosa L.): An evidence-based systematic review by the Natural Standard Research Collaboration. Journal of Herbal Pharmacotherapy. 2007.
• Drugs.com Natural Products Database: Banaba Uses, Benefits & Dosage. Last updated July 22, 2025.
• WO2005099486A1 – Process for preparing Lagerstroemia speciosa L. extract. Google Patents.
• A Systematic Review on Banaba. IJRAR. 2020.
• Ellagitannins from Lagerstroemia speciosa as Activators of Glucose Transport in Fat Cells. ResearchGate.